Related references
Note: Only part of the references are listed.The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells
Paul A. Clark et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2017)
HOUT-06. TTFIELDS FOR NEWLY DIAGNOSED GLIOBLASTOMA: IMPACT OF CONSULTATION STRATEGY
Martin Proescholdt et al.
NEURO-ONCOLOGY (2017)
ACTR-27. COMPLIANCE AND TREATMENT DURATION PREDICT SURVIVAL IN A PHASE 3 EF-14 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Zvi Ram et al.
NEURO-ONCOLOGY (2017)
Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: A computer modeling study
Anders Rosendal Korshoej et al.
PLOS ONE (2017)
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Wojciech Szopa et al.
BIOMED RESEARCH INTERNATIONAL (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma
Christina Schaub et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Tumor treating fields: a novel treatment modality and its use in brain tumors
Andreas F. Hottinger et al.
NEURO-ONCOLOGY (2016)
Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy
Marlon Garzo Saria et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2016)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study
Aafia Chaudhry et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2015)
Treatment of Elderly Patients With Glioblastoma A Systematic Evidence-Based Analysis
Oren J. Zarnett et al.
JAMA NEUROLOGY (2015)
Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100A™ System Versus Best Physician's Choice Chemotherapy
Andrew A. Kanner et al.
SEMINARS IN ONCOLOGY (2014)
Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)
Maciej M. Mrugala et al.
SEMINARS IN ONCOLOGY (2014)
Treatment options and outcomes for glioblastoma in the elderly patient
Nils D. Arvold et al.
CLINICAL INTERVENTIONS IN AGING (2014)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
